The online version of this article (doi:10.1186/2045-7022-4-40) contains supplementary material, which is available to authorized users.
Shigeru Kinoshita has received funding for his research from Otsuka Pharmaceutical Co.
MU collected the tears, examined their cytokine levels, wrote the text, and prepared the table and figures. MU, JS, CS, and SK contributed to the research and reviewed the manuscript. All authors read and approved the final manuscript.
Rebamipide eyedrops are approved in Japan for the treatment of dry eye disease. Some patients with allergic conjunctival diseases also manifest dry eye. Earlier we reported that rebamipide suppressed polyI:C-induced inflammatory cytokines in human conjunctival epithelial cells. In the current study we examined the effect of rebamipide eyedrops on the level of interleukin-8 (IL-8), eosinophil cationic protein (ECP), and total IgE on the ocular surface.
We prescribed rebamipide eyedrops to patients with atopic keratoconjunctivitis (AKC) who presented with dry eye (6 eyes in 4 AKC patients) and measured the IL-8, ECP, and total IgE levels in their tears before- and 2, and 4–6 weeks after the start of rebamipide treatment. To measure the IL-8 and total IgE levels in their tears we used BD™ CBA Flex sets; ECP measurements were with ELISA. The level of IL-8, ECP, and total IgE in the tears of AKC patients was reduced significantly 4–6 weeks after the start of rebamipide treatment. We also recorded subjective symptoms associated with AKC, e.g. itching, foreign body sensation, and eye mucus discharge, by using a patient questionnaire. Their subjective symptoms associated with AKC were also significantly ameliorated at 2 and 4–6 weeks.
Our observations suggest that the anti-inflammatory effects of rebamipide eyedrops help to combat human ocular surface inflammation and that they may be a new effective therapy in patients with AKC.
Additional file 1: Figure S1: The change in the tear level of IP-10 and MCP-1 in the six eyes. Pretreatment levels are recorded as 1 on the y axis. The length of treatment is indicated on the x axis. (PPTX 99 KB)13601_2014_1075_MOESM1_ESM.pptx
Additional file 2: Figure S2: Photographs of the upper palpebral conjunctiva of each eye before- and 2 and 4-6 weeks after the start of treatment with rebamipide eyedrops. (PPTX 372 KB)13601_2014_1075_MOESM2_ESM.pptx
Additional file 3: Figure S3:a. IL-8, ECP and total IgE levels before- and 2 and 4-6 weeks after the start of treatment with tacrolimus eyedrops in the tear of right eye of case 4, which was treated with tacrolimus, an immunosuppressant. b. IL-8, ECP and total IgE levels before- and 2 and 4-6 weeks after the start of treatment with rebamipide eyedrops in the tear of left eye of case 3, which was treated with both rebamipide and 0.1% fluorometholone, a steroid eyedrop. (PPTX 92 KB)13601_2014_1075_MOESM3_ESM.pptx
Authors’ original file for figure 113601_2014_1075_MOESM4_ESM.tif
Authors’ original file for figure 213601_2014_1075_MOESM5_ESM.tif
Authors’ original file for figure 313601_2014_1075_MOESM6_ESM.tif
Ishihara K, Komuro Y, Nishiyama N, Yamasaki K, Hotta K: Effect of rebamipide on mucus secretion by endogenous prostaglandin-independent mechanism in rat gastric mucosa. Arzneimittelforschung. 1992, 42: 1462-1466. PubMed
- Downregulation of IL-8, ECP, and total IgE in the tears of patients with atopic keratoconjunctivitis treated with rebamipide eyedrops
- BioMed Central
Neu im Fachgebiet HNO
Mail Icon II